What’s new

• Sachin Srivastava appointed as Whole Time Director and CEO from June 13, 2026.
• Resignation of Executive Director Karthik Iyer accepted, effective same day.
• Srivastava's pharma background aligns with Relic's pivot to pharma and wellness.

Why it matters

For a nano-cap with near-zero revenue and a restructuring underway, this leadership change signals a focused push into pharma. But the lack of quantified financial targets means the move is notable, not a confirmed turnaround.

What we’re watching

• First quarterly results under Srivastava's leadership.
• Any update on pharma subsidiary performance or orders.
• Management guidance on revenue breakeven timelines.

The full read

Relic Technologies is betting its future on pharma. The nano-cap, which has near-zero revenue and a market cap of just ₹40 crore, has brought in Sachin Srivastava, a pharma sales veteran with 25 years of experience, as its new Whole Time Director and CEO. Concurrently, Executive Director Karthik Iyer has resigned. The move is the clearest signal yet that Relic intends to execute on its pharma pivot, but it remains a bet without financial proof. The company's restructuring context reduces the element of surprise, and the board meeting lasted only 30 minutes — a routine procedure. The open question is whether Srivastava can convert intent into revenue.

Primary source: BSE · NSE